Maria Themeli

3.2k total citations · 1 hit paper
41 papers, 2.2k citations indexed

About

Maria Themeli is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Maria Themeli has authored 41 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in Maria Themeli's work include CAR-T cell therapy research (27 papers), Immune Cell Function and Interaction (11 papers) and CRISPR and Genetic Engineering (7 papers). Maria Themeli is often cited by papers focused on CAR-T cell therapy research (27 papers), Immune Cell Function and Interaction (11 papers) and CRISPR and Genetic Engineering (7 papers). Maria Themeli collaborates with scholars based in Netherlands, United States and Greece. Maria Themeli's co-authors include Michel Sadelain, V D Fedorov, Niels W.C.J. van de Donk, Tuna Mutis, Esther Drent, Renée Poels, Fabiana Perna, Mithat Gönen, Christopher C. Kloss and Giovanni Ciriello and has published in prestigious journals such as Blood, Nature Biotechnology and PLoS ONE.

In The Last Decade

Maria Themeli

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

2013 604 citations V D Fedorov, Maria Themeli et al. profile →

Peers

Countries citing papers authored by Maria Themeli

Since Specialization

Citations

This map shows the geographic impact of Maria Themeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Themeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Themeli more than expected).

Fields of papers citing papers by Maria Themeli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Themeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Themeli. The network helps show where Maria Themeli may publish in the future.

Co-authorship network of co-authors of Maria Themeli

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Themeli. A scholar is included among the top collaborators of Maria Themeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Themeli. Maria Themeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T‐cell therapy 2025 ·HemaSphere ·(unknown), (unknown), Renée Poels, (unknown), (unknown), (unknown), Jennemiek van Arkel, (unknown), Niels W.C.J. van de Donk, Maria Themeli, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Rebecca M. Richards, Tuna Mutis	0
2	Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease 2025 ·Biomolecules ·Jiaxian Wang, (unknown), Ricardo De Matos Simoes, (unknown), Ruud Ruiter, Henk‐Jan Prins, (unknown), Huipin Yuan, Joost D. de Bruijn, Anton C. Martens, Constantine S. Mitsiades, Sonja Zweegman, Maria Themeli, Richard W.J. Groen	0
3	Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Christie P.M. Verkleij, Diane Le Clerre, Maria Themeli, Isabelle Chion-Sotinel, Sonja Zweegman, Román Galetto, Tuna Mutis, Niels W.C.J. van de Donk	5
4	Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation 2024 ·Frontiers in Immunology ·(unknown), Laura García-Pérez, Maria Themeli	12
5	Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138 2023 ·Clinical Cancer Research ·(unknown), (unknown), Jennemiek van Arkel, (unknown), Afroditi Katsarou, Ruud Ruiter, (unknown), Huipin Yuan, Joost D. de Bruijn, Sonja Zweegman, Niels W.C.J. van de Donk, Richard W.J. Groen, Maria Themeli, Tuna Mutis	10
6	Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells 2022 ·Nature Biomedical Engineering ·Sjoukje J. C. van der Stegen, (unknown), Roseanna M. Petrovic, Hongyao Xie, (unknown), Vera Alexeeva, Yuzhe Shi, Jorge Mansilla‐Soto, Mohamad Hamieh, Justin Eyquem, Annalisa Cabriolu, Xiuyan Wang, Ramzey Abujarour, Tom T. Lee, Raedun Clarke, Bahram Valamehr, Maria Themeli, Isabelle Rivière, Michel Sadelain	49
7	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis 2021 ·Clinical Cancer Research ·(unknown), (unknown), Afroditi Katsarou, Renée Poels, (unknown), Esther Drent, (unknown), Fengzhi Li, Sonja Zweegman, Niels W.C.J. van de Donk, Maria Themeli, Richard W.J. Groen, Tuna Mutis	47
8	Protocol for Isolation, Stimulation and Functional Profiling of Primary and iPSC-derived Human NK Cells 2020 ·BIO-PROTOCOL ·Janine Melsen, Maria Themeli, (unknown), Els van Beelen, Gertjan Lugthart, Rob C. Hoeben, Marco W. Schilham, Harald Mikkers	4
9	Rapid and Reproducible Differentiation of Hematopoietic and T Cell Progenitors From Pluripotent Stem Cells 2020 ·Frontiers in Cell and Developmental Biology ·Léa Flippe, Anne Gaignerie, (unknown), Olivier Baron, Xavier Saulquin, Maria Themeli, Carole Guillonneau, Laurent David	10
10	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells 2019 ·Clinical Cancer Research ·Esther Drent, Renée Poels, Ruud Ruiter, Niels W.C.J. van de Donk, Sonja Zweegman, Huipin Yuan, Joost D. de Bruijn, Michel Sadelain, Henk M. Lokhorst, Richard W.J. Groen, Tuna Mutis, Maria Themeli	135
11	The tumor vasculature an attractive CAR T cell target in solid tumors 2019 ·Angiogenesis ·(unknown), Elisabeth J. M. Huijbers, Maria Themeli, Arjan W. Griffioen, Judy R. van Beijnum	30
12	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design 2018 ·PLoS ONE ·Esther Drent, Renée Poels, Manon Mulders, Niels W.C.J. van de Donk, Maria Themeli, Henk M. Lokhorst, Tuna Mutis	62
13	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization 2017 ·Molecular Therapy ·Esther Drent, Maria Themeli, Renée Poels, (unknown), Huipin Yuan, Joost D. de Bruijn, Anton C. Martens, Sonja Zweegman, Niels W.C.J. van de Donk, Richard W.J. Groen, Henk M. Lokhorst, Tuna Mutis	216
14	Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene 2016 ·Molecular Therapy — Nucleic Acids ·Andriana G. Kotini, Elisa de Stanchina, Maria Themeli, Michel Sadelain, Eirini P. Papapetrou	24
15	The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells 2015 ·Stem Cell Reports ·Fabiana Perna, Ly Vu, Maria Themeli, Sonja Kriks, Ruben Hoya-Arias, Raya Khanin, Todd Hricik, Jorge Mansilla‐Soto, Eirini P. Papapetrou, Ross L. Levine, Lorenz Studer, Michel Sadelain, Stephen D. Nimer	5
16	New Cell Sources for T Cell Engineering and Adoptive Immunotherapy 2015 ·Cell stem cell ·Maria Themeli, Isabelle Rivière, Michel Sadelain	132
17	Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy 2013 ·Nature Biotechnology ·Maria Themeli, Christopher C. Kloss, Giovanni Ciriello, V D Fedorov, Fabiana Perna, Mithat Gönen, Michel Sadelain	358
18	Horizontal DNA Transfer from Donor to Host Cells as an Alternative Mechanism of Epithelial Chimerism after Allogeneic Hematopoietic Cell Transplantation 2010 ·Biology of Blood and Marrow Transplantation ·Miguel Waterhouse, Maria Themeli, Hartmut Bertz, Nicholas Zoumbos, Jürgen Finke, Alexandros Spyridonidis	18
19	Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia 2010 ·Leukemia ·Maria Themeli, (unknown), Miguel Waterhouse, Hartmut Bertz, Eleni D. Lagadinou, Nicholas Zoumbos, Jürgen Finke, A. Spyridonidis	28
20	Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia 2010 ·Bone Marrow Transplantation ·Alexandros Spyridonidis, Maria Liga, Evangelos Triantafyllou, Maria Themeli, Markos Marangos, Μαρίνα Καρακάντζα, Nicholas Zoumbos	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact